BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.30−0.20 (-2.67%)
Close on Nov 18, 2026Market cap $1.87BP/E –Yield –
BioCryst Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BioCryst Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$313.16M, down 677.8% year over year. For fiscal 2025 it was $340.99M. The highest annual figure on record is $340.99M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.99M | – |
| FY2024 | Dec 31, 2024 | -$2.54M | – |
| FY2023 | Dec 31, 2023 | -$103.71M | – |
| FY2022 | Dec 31, 2022 | -$148.44M | – |
| FY2021 | Dec 31, 2021 | -$177.72M | – |
| FY2020 | Dec 31, 2020 | -$174.76M | – |
| FY2019 | Dec 31, 2019 | -$99.46M | – |
| FY2018 | Dec 31, 2018 | -$94.22M | – |
| FY2017 | Dec 31, 2017 | -$57.41M | – |
| FY2016 | Dec 31, 2016 | -$48.61M | – |
| FY2015 | Dec 31, 2015 | -$39.44M | – |
| FY2014 | Dec 31, 2014 | -$45.77M | – |
| FY2013 | Dec 31, 2013 | -$30.72M | – |
| FY2012 | Dec 31, 2012 | -$33.89M | – |
| FY2011 | Dec 31, 2011 | -$49.59M | – |
| FY2010 | Dec 31, 2010 | -$34.36M | – |
| FY2009 | Dec 31, 2009 | -$13.74M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $98.47M | +230.6% |
| Q1 FY2026 | Mar 31, 2026 | -$701.60M | -3405.2% |
| Q4 FY2025 | Dec 31, 2025 | $260.39M | – |
| Q3 FY2025 | Sep 30, 2025 | $29.59M | +284.7% |
| Q2 FY2025 | Jun 30, 2025 | $29.79M | +240.0% |
| Q1 FY2025 | Mar 31, 2025 | $21.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.51M | – |
| Q3 FY2024 | Sep 30, 2024 | $7.69M | – |
| Q2 FY2024 | Jun 30, 2024 | $8.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$42.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$46.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$44.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$42.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$38.51M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$109.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$35.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$34.92M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.26M | – |
| Q3 FY2018 | Sep 30, 2018 | -$28.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.25M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.21M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.35M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.69M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.19M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.24M | – |
See a number that looks wrong?